Search for: All records

A 28-GHz multibeam joint communication and sensing system called SideSense is presented, in which a line-of-sight (LoS) beam is used to maintain reliable communication, while other sensing beams are used to enhance physiological motion detection. SideSense decodes the motion frequency and shape from the channel state information (CSI) by first tuning the gain ratio and phase differences between the LoS communication beam and non-LoS (NLoS) beam to maximize the sensing signal-to-noise ratio (SSNR) without significantly degrading the communication channel capacity (CCC). Analytical results based on a bistatic model are presented to show a gain ratio of around 1 and a phase difference of 90° or 270°, which are ideal for optimizing both SSNR and CCC. Experiments based on an array of phased array (APA) beamformers and orthogonal frequency-division multiplexing (OFDM) waveforms with phantom and human subjects are presented to validate the performance of SideSense. Results show that SideSense can improve SSNR by 84% while reducing CCC by 35%, an acceptable decrease within the normal operational parameters of a millimeter-wave (mmWave) communication system, which would not trigger a link reestablishment procedure, e.g., communication beam realignment. 

In this study, we report a novel platinum–doxorubicin conjugate that demonstrates superior therapeutic indices to cisplatin, doxorubicin, or their combination, which are commonly used in cancer treatment. This new molecular structure (1) was formed by conjugating an amphiphilic Pt(IV) prodrug of cisplatin with doxorubicin. Due to its amphiphilic nature, the Pt(IV)–doxorubicin conjugate effectively penetrates cell membranes, delivering both cisplatin and doxorubicin payloads intracellularly. The intracellular accumulation of these payloads was assessed using graphite furnace atomic absorption spectrometry and fluorescence imaging. Since the therapeutic effects of cisplatin and doxorubicin stem from their ability to target nuclear DNA, we hypothesized that the amphiphilic Pt(IV)–doxorubicin conjugate (1) would effectively induce nuclear DNA damage toward killing cancer cells. To test this hypothesis, we used flow the cytometric analysis of phosphorylated H2AX (γH2AX), a biomarker of nuclear DNA damage. The Pt(IV)–doxorubicin conjugate (1) markedly induced γH2AX in treated MDA-MB-231 breast cancer cells, showing higher levels than cells treated with either cisplatin or doxorubicin alone. Furthermore, MTT cell viability assays revealed that the enhanced DNA-damaging capability of complex 1 resulted in superior cytotoxicity and selectivity against human cancer cells compared to cisplatin, doxorubicin, or their combination. Overall, the development of this amphiphilic Pt(IV)–doxorubicin conjugate represents a new form of combination therapy with improved therapeutic efficacy.